Hook / Thesis
Enact Holdings (ACT) is running the company. The mortgage insurance franchise is cash-generative, well-capitalized and is explicitly returning capital through a rising dividend and large share repurchases. Those returns are the clearest, measurable driver of value for the stock today.
At roughly $41.79 per share and a market capitalization near $5.83 billion, the balance-sheet strengths (low leverage, robust ROE) plus capital actions make a straightforward trade: buy on a measured pullback and ride the combination of earnings power, buybacks and a higher dividend to a sensible valuation reset toward $50 over the next 180 trading days.
What the company does and why the market should care
Enact Holdings is a holding company whose core asset is a private mortgage insurance business. It provides credit protection to mortgage lenders and investors by covering a portion of unpaid principal balances on mortgage loans. The economics of mortgage insurance are simple when execution and capital discipline are intact: premiums collected on low-loss vintages turn into high-margin earnings and distributable cash.
Investors should care because Enact has been translating that cash into shareholder returns. The company announced a 14% increase to the quarterly dividend to $0.24 per share (payable 06/18/2026 to holders of record 05/28/2026) and authorized a $500 million share repurchase program in addition to an existing $350 million program earlier in the year. Those actions create direct, predictable value accretion while management maintains a conservative capital posture (A- rating for Enact Re and positive commentary on PMIERs compliance).
Supporting numbers
Key data points to keep in mind:
- Current price: $41.79 (previous close: $40.95).
- Market cap: $5.83 billion.
- Trailing earnings per share: $4.84; price-to-earnings about 8.6x.
- Price-to-book: ~1.09x; ROE: 12.66%; ROA: 9.71%.
- Dividend: $0.24 quarterly; yield ~ 2.08%.
- Debt-to-equity: 0.14 - conservative leverage for an insurer.
- EV/EBITDA: ~6.66x, EV/Sales: ~4.86x.
Those metrics describe a profitable, low-leverage insurance operator trading at a single-digit P/E with double-digit ROE and active capital returns - a combination that supports a valuation multiple upgrade if growth and capital returns continue.
Valuation framing
At the current price and EPS of $4.84, ACT trades below $50 using modest multiples: the market is valuing the shares at roughly 8.6x trailing earnings. If the business sustains earnings and buybacks reduce share count while management redeploys capital sensibly, a shift toward a low-double-digit P/E (10-11x) would be justified. That math points toward a $48-$53 range without implying dramatic operational improvement.
Price-to-book around 1.09x and EV/EBITDA below 7x also look conservative for a well-rated, cash-generative mortgage insurer. The A- rating for Enact Re and the company's commentary that updated PMIERs have an immaterial impact on capital further underpins the argument that the market can price a margin-of-safety around existing returns.
Catalysts (near- to medium-term)
- Dividend increase and payout cadence - the 14% raise to $0.24 (announced 05/05/2026) validates management’s willingness to return excess capital.
- Aggressive buybacks - a new $500 million repurchase authorization (02/03/2026) on top of $350 million previously authorized materially lowers share count and boosts EPS.
- Ratings momentum - continued strong capital metrics and low loss incidence could lead to further credit-quality acknowledgment and lower required capital costs.
- Regulatory clarity - confirmation that PMIERs changes are immaterial to Enact’s capital position reduces a tail regulatory risk.
- Quarterly earnings beats - delivered results at, or above, consensus will reinforce the narrative of cash generation and expand the multiple assigned by the market.
Technical and market context
Technicals are mixed: the 10-day SMA sits near $41.77 and the 50-day/20-day SMAs are modestly higher, while momentum indicators show a slightly bearish MACD and an RSI of ~46, suggesting the stock is consolidating after recent strength and offering a disciplined entry window. Average daily volume near ~313k shares provides adequate liquidity for the trade. Note the 52-week range: low $33.94, high $44.80 - a pullback toward the mid-$30s has precedent.
Trade plan (actionable)
Trade idea: Long ACT on pullback with a primary target toward $50 over a 180 trading day horizon.
- Entry price: $41.00. I prefer buying on a small dip under current levels to get a better cost basis; this price is within a reasonable range of recent action and SMA support.
- Stop loss: $37.00. A close below $37 would indicate technical weakness and risk to the next support band around the 52-week low.
- Target price: $50.00 over the next 180 trading days (long term - 180 trading days). This implies a modest rerating toward a 10-11x P/E on stable earnings and the benefit of share reductions from buybacks.
Horizon rationale: mortgage insurers’ returns compound over quarters as premiums collect and loss performance is realized. The long-term window (180 trading days) gives time for repurchases to be executed, for at least two quarterly dividends to land, and for a couple of earnings reports to demonstrate continued capital returns.
Position sizing & trade management
This is a medium-risk position for investors looking for income plus upside from buybacks. Consider sizing the trade to reflect your portfolio risk tolerance; because of potential housing-cycle sensitivity, keep position size moderate (single-digit percent of equity portfolio). Reassess on each quarterly report and tighten stops into material upside or if the company announces unexpectedly dilutive actions.
Risks and counterarguments
Below are the main risks that could invalidate the thesis, followed by a concise counterargument to my own bullish view.
- Housing-cycle shock: A surprise turn in mortgage delinquencies or a rapid decline in home prices would increase claims and hit earnings and capital, pressuring the stock.
- Regulatory or PMIERs changes: While recent commentary suggested immaterial impact, future regulatory tightening or higher capital charges could reduce distributable capital.
- Interest-rate and origination environment: A prolonged slump in mortgage origination reduces new premium flows and could compress growth in insured volumes.
- Execution risk on reinsurance and capital actions: If reinsurance costs rise materially or buybacks are ill-timed, the EPS accretion story could stall.
- Market multiple compression: Even with solid earnings, macro-driven multiple contraction could keep the stock stuck at current levels or lower.
Counterargument: The market may be discounting ACT because mortgage insurers are inherently cyclical. If origination volumes decline faster than expected or loss pick-up emerges in older vintages, earnings could fall and dividends/repurchases could be paused. In that scenario, the current P/E would look less attractive and the stock could retest the $34 area.
What would change my mind
I would downgrade this bullish stance if any of the following occur:
- Material deterioration in default or loss metrics across insured vintages reported on a quarterly basis.
- A pause or reversal in share repurchase activity or dividend cuts, which would suggest capital constraints.
- A negative regulatory development that meaningfully increases PMIERs capital requirements or forces asset sales at depressed prices.
Conclusion
Enact’s mortgage insurance business is the tangible engine behind Enact Holdings’ valuation. Strong profitability (EPS $4.84), a conservative balance sheet (debt/equity ~0.14), an A- reinsurance rating and explicit capital returns via a rising dividend and sizeable buybacks create a compelling, cash-backed investment case. The trade here is straightforward: buy on weakness around $41.00 with a stop at $37.00 and a target of $50.00 over the next 180 trading days, while monitoring loss trends, regulatory developments and buyback execution. This is a measured, data-driven way to own a cash-yielding insurer that is actively converting capital into shareholder value.
Key timing notes
Dividend payable: 06/18/2026 (record date: 05/28/2026). Keep an eye on quarterly reports and any updated guidance on repurchase execution that could accelerate EPS accretion.